[go: up one dir, main page]

IL131212A0 - Recombinant virus and live-virus vaccines - Google Patents

Recombinant virus and live-virus vaccines

Info

Publication number
IL131212A0
IL131212A0 IL13121299A IL13121299A IL131212A0 IL 131212 A0 IL131212 A0 IL 131212A0 IL 13121299 A IL13121299 A IL 13121299A IL 13121299 A IL13121299 A IL 13121299A IL 131212 A0 IL131212 A0 IL 131212A0
Authority
IL
Israel
Prior art keywords
virus
live
vaccines
recombinant
recombinant virus
Prior art date
Application number
IL13121299A
Original Assignee
Yissum Res Dev Co
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Hadasit Med Res Service filed Critical Yissum Res Dev Co
Priority to IL13121299A priority Critical patent/IL131212A0/en
Priority to AU63130/00A priority patent/AU6313000A/en
Priority to JP2001513617A priority patent/JP2003505103A/en
Priority to CA 2381056 priority patent/CA2381056A1/en
Priority to IL14784100A priority patent/IL147841A0/en
Priority to PCT/IL2000/000469 priority patent/WO2001009361A1/en
Priority to EP20000949877 priority patent/EP1210448A1/en
Publication of IL131212A0 publication Critical patent/IL131212A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13121299A 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines IL131212A0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL13121299A IL131212A0 (en) 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines
AU63130/00A AU6313000A (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
JP2001513617A JP2003505103A (en) 1999-08-03 2000-08-03 Recombinant HSV-1 and live virus vaccine
CA 2381056 CA2381056A1 (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
IL14784100A IL147841A0 (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
PCT/IL2000/000469 WO2001009361A1 (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines
EP20000949877 EP1210448A1 (en) 1999-08-03 2000-08-03 Recombinant hsv-1 and live viral vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13121299A IL131212A0 (en) 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines

Publications (1)

Publication Number Publication Date
IL131212A0 true IL131212A0 (en) 2001-01-28

Family

ID=11073099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13121299A IL131212A0 (en) 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines

Country Status (6)

Country Link
EP (1) EP1210448A1 (en)
JP (1) JP2003505103A (en)
AU (1) AU6313000A (en)
CA (1) CA2381056A1 (en)
IL (1) IL131212A0 (en)
WO (1) WO2001009361A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063835B2 (en) * 2000-01-21 2006-06-20 Biovex Limited Virus strains
WO2002086105A1 (en) * 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
JP2004099584A (en) 2002-05-02 2004-04-02 Keio Gijuku Anti-tumor agent using HSV
US7592169B2 (en) 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
JP5639361B2 (en) * 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア HSV-1 and HSV-2 vaccines and methods of use thereof
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2674051C (en) 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN102657861A (en) * 2010-08-16 2012-09-12 郑州金森生物科技工程有限公司 Herpes simplex virus I-type gene recombinant attenuated live vaccine and preparation method thereof
SMT201900033T1 (en) * 2011-09-08 2019-02-28 Univ New York Oncolytic herpes simplex virus and therapeutic uses thereof
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
CA3132867A1 (en) * 2019-03-14 2020-09-17 Research Institute At Nationwide Children's Hospital Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
CN111635913B (en) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 Constructs and their applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors

Also Published As

Publication number Publication date
EP1210448A1 (en) 2002-06-05
CA2381056A1 (en) 2001-02-08
WO2001009361A1 (en) 2001-02-08
AU6313000A (en) 2001-02-19
JP2003505103A (en) 2003-02-12

Similar Documents

Publication Publication Date Title
GB2337755B (en) Virus vaccine
SI1150712T1 (en) Human papilloma virus vaccine formulations
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
AU2003235707A8 (en) Immunogenic preparations and vaccines on the basis of mrna
SI1208214T1 (en) Genetically engineered bleb vaccine
IL148455A0 (en) Vaccine against hbv and hpv
DK1058558T3 (en) Recombinant and adjuvanted influenza and herpes virus vaccines
HUP0202885A3 (en) Vaccines
EP1112091A4 (en) Rapid cryobaric sterilization and vaccine preparation
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
IL131212A0 (en) Recombinant virus and live-virus vaccines
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
ZA200108263B (en) Novel recombinant and mutant herpesviruses.
EP1204424A4 (en) Recombinant rsv virus expression systems and vaccines
GB9901254D0 (en) Vaccines
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
HUP0202770A3 (en) Human papilloma virus vaccine
IL148191A0 (en) Recombinant subunit vaccine
EP1113777A4 (en) Novel hepatitis c virus peptides and uses thereof
EP1086215A4 (en) Preparation and use of superior vaccines
AU2002318104A1 (en) Microparticles and methods for delivery of recombinant viral vaccines
AU5913801A (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
GB9916794D0 (en) In vitro virus reconstitution
AU2946395A (en) Recombinant infectious laryngotracheitis virus and vaccine
EP1224939A4 (en) Interferon complex and medicinal use thereof